However, only 52 (2.8%) patients with BRAF-altered CRC and 11 (1.6%) patients with a BRAF-altered non-CRC GI malignancy had received a BRAF inhibitor, limiting further analysis. The gene discussed is BRAF; the disease is colorectal carcinoma.